HPC2 variants and screen-detected prostate cancer |
| |
Authors: | Vesprini D Nam R K Trachtenberg J Jewett M A Tavtigian S V Emami M Ho M Toi A Narod S A |
| |
Institution: | Department of Public Health Sciences, University of Toronto, Toronto, Ontario, Canada. |
| |
Abstract: | Two studies have reported significant associations between susceptibility to prostate cancer and two common missense variants of the HPC2/ELAC2 gene, with estimated relative risks in the range of two- to threefold. We investigated whether these polymorphisms could be informative in the prediction of the presence of prostate cancer in men undergoing prostatic biopsy for the evaluation of an elevated serum-PSA level (> or = 4.0 ng/ml). We genotyped 944 men who underwent a prostate biopsy at our institution, as well as a control population of 922 healthy, unselected women from the same population. The prevalence of the HPC2 Ala541Thr allele was similar in men with prostate cancer (6.3%), men with other prostatic conditions (6.8%), and healthy women (6.3%) (P = .83). We conclude that HPC2 genotyping is unlikely to be a useful adjunct to PSA in the prediction of the presence of biopsy-detected prostate cancer in asymptomatic men. |
| |
Keywords: | |
本文献已被 PubMed 等数据库收录! |
|